Docetaxel 80mg Injection
Generic Name: Docetaxel
Strength: 80 mg per vial
Dosage Form: Concentrate / solution for intravenous infusion
Medicine Class: Taxane chemotherapy medicine (microtubule inhibitor)
Manufacturer/Brand: Intas / Taxocare 80mg
Docetaxel 80 mg Injection is a chemotherapy medicine used to treat several types of cancer, including breast, lung, and prostate cancer. It belongs to a class of medicines called taxanes, which interfere with cell division to help slow or stop the growth of cancer cells.
Docetaxel 80 mg Injection contains docetaxel, an anticancer medicine classified as a taxane and microtubule inhibitor. It is supplied in a vial for administration into a vein by a qualified healthcare professional.
Docetaxel is used alone or in combination with other cancer medicines, depending on the cancer type, treatment plan and clinical circumstances.
Docetaxel 80 mg Injection may be prescribed to:
Treat locally advanced or metastatic breast cancer.
Treat certain forms of non-small cell lung cancer.
Treat metastatic castration-resistant prostate cancer, generally in combination with prednisone.
Treat advanced gastric or gastro-oesophageal junction adenocarcinoma as part of combination chemotherapy.
Treat locally advanced squamous cell carcinoma of the head and neck as part of combination chemotherapy.
Approved uses and treatment combinations may vary by country and product label. The appropriate treatment and dose should be determined by an oncologist based on the cancer type, previous treatment and individual clinical factors.
Docetaxel works by targeting structures inside cells called microtubules. These structures help cells divide and multiply.
The medicine stabilises microtubules and prevents them from breaking down normally during cell division. This disrupts the multiplication of cancer cells and can lead to their death.
Take Docetaxel exactly as prescribed by your healthcare professional.
Docetaxel is administered as an intravenous infusion into a vein by a trained healthcare professional.
Infusions are commonly given over approximately one hour, with treatment intervals and cycles determined by the prescribed chemotherapy regimen.
The dose is calculated by the oncology team and may be adjusted according to treatment response, blood counts, liver function and side effects.
Corticosteroid premedication is generally prescribed to reduce the risk of fluid retention and certain allergic reactions.
Blood tests and clinical monitoring are required during treatment.
Do not attempt to inject, prepare or administer this medicine yourself.
Tell your oncologist about your medical history and all medicines, supplements and herbal products you use before starting docetaxel.
Additional caution or assessment is particularly important if you:
Have liver disease or abnormal liver function tests.
Have low white blood cell or neutrophil counts.
Have a history of severe allergic reactions to docetaxel or ingredients such as polysorbate 80.
Have a history of fluid retention, swelling or heart problems.
Have nerve problems or significant peripheral neuropathy.
Have an active infection or are experiencing unexplained fever.
Important interactions:
Medicines that affect the CYP3A4 liver enzyme may alter docetaxel levels. These include certain antifungal medicines, antibiotics, antiviral medicines and other drugs that inhibit or induce this enzyme. Some cancer medicines and other treatments may also increase the risk of side effects when used together.
Docetaxel can cause significant reductions in blood cell counts and may affect liver function. Blood tests and other monitoring are therefore important throughout treatment.
Check all possible interactions and precautions with your oncologist or pharmacist before treatment.
Docetaxel can cause harm to an unborn baby and is generally not recommended during pregnancy. Pregnancy status should be assessed before treatment where applicable, and effective contraception is recommended during treatment. The required period of contraception after the final dose should be confirmed with the treating oncologist.
Breastfeeding is not recommended during docetaxel treatment. Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss the risks and treatment options with their oncology team.
Like all medicines, Docetaxel can cause side effects, although not everyone experiences them.
Common or recognised side effects may include:
Hair loss.
Nausea and vomiting.
Diarrhoea or constipation.
Mouth sores or inflammation.
Tiredness and weakness.
Loss of appetite.
Muscle or joint pain.
Changes in fingernails or toenails.
Numbness, tingling or other nerve-related symptoms.
Swelling caused by fluid retention.
Seek urgent medical attention if you develop a fever, signs of infection, difficulty breathing, severe allergic symptoms, unusual bleeding or bruising, severe diarrhoea or significant swelling. These may indicate serious complications, including low blood cell counts, hypersensitivity or fluid retention.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Docetaxel according to the instructions shown on the original product packaging.
Keep the vial in its original packaging to protect it from light where specified.
Storage conditions may vary depending on the formulation and manufacturer.
Docetaxel is a cytotoxic medicine and must be handled and disposed of according to applicable healthcare and pharmacy procedures.
Keep out of reach of children.
Do not use after the expiry date printed on the packaging.
Docetaxel is a chemotherapy medicine used to treat several cancers, including certain types of breast, lung, prostate, stomach and head and neck cancer. Its use depends on the cancer diagnosis and treatment plan.
It is given into a vein as an intravenous infusion by a trained healthcare professional, usually in a hospital or oncology treatment centre. It must not be self-administered.
Treatment is commonly organised into cycles, often at intervals of three weeks. The schedule and number of cycles depend on the cancer type, combination medicines and the patient's response to treatment.
Corticosteroids are generally prescribed before docetaxel to reduce the risk of fluid retention and certain hypersensitivity reactions. Follow the premedication schedule provided by the oncology team.
Hair loss is a recognised side effect of docetaxel and may affect scalp and body hair. The extent and timing can vary between individuals.
Regular blood tests are needed to monitor blood cell counts and liver function. The oncology team may also assess side effects such as infection, fluid retention and nerve-related symptoms before each treatment cycle.
Docetaxel can harm an unborn baby and is generally not recommended during pregnancy. Breastfeeding is not recommended during treatment; discuss contraception and pregnancy planning with the treating oncologist.